Transformants (e.g., Recombinant Dna Or Vector Or Foreign Or Exogenous Gene Containing, Fused Bacteria, Etc.) Patents (Class 435/252.3)
  • Patent number: 10781241
    Abstract: The present invention relates to providing improved cell-permeable (iCP)-SOCS3 recombinant protein and uses thereof. Preferably, the iCP-SOCS3 recombinant protein may be used as protein-based anti-pancreatic cancer agent by utilizing the platform technology for macromolecule intracellular transduction.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: September 22, 2020
    Assignee: CELLIVERY THERAPEUTICS, INC.
    Inventor: Daewoong Jo
  • Patent number: 10781989
    Abstract: The diffraction lens has an incident side and an exit side that are both convexly shaped, includes an exit diffraction plane that has an absolute value for the order of diffraction of 5 or greater and is disposed on the exit side, and is shaped such that the absolute value of a curvature at the surface apex of an envelope surface of the exit diffraction plane is smaller than the absolute value of a curvature at the surface apex of an incident surface, or the absolute value of the amount of sag in the direction of the optical axis at an outer periphery of the envelope surface of the exit diffraction plane is smaller than the maximum absolute value of the amount of sag in the direction of the optical axis at an outer periphery of the incident surface.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: September 22, 2020
    Assignee: MAXELL JOEI TECH CO., LTD.
    Inventor: Takeshi Shimano
  • Patent number: 10774391
    Abstract: The present invention relates to a recombinant bacterium based on a non-pathogenic bacterium that has a modified genome containing a nucleic acid of interest from a pathogen that is detected by a molecular diagnostic assay and that mimics the diagnostic profile of the pathogen. The invention further relates to a diagnostic control composition comprising the recombinant bacterium and to methods for producing the recombinant bacterium. The recombinant bacterium is a safe, reliable quality control for the detection of pathogens such as Mycobacterium tuberculosis and Staphylococcus aureus. The invention also relates to a kit comprising either the recombinant bacterium, compositions containing the recombinant bacterium or bacteria produced according to the method of the invention.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: September 15, 2020
    Assignee: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Bavesh Davandara Kana, Edith Erika Machowski
  • Patent number: 10765094
    Abstract: The present invention provides a method for detection of an inflammatory reaction, which comprises using a transformant or transgenic non-human animal transfected with a vector comprising a promoter for a gene encoding an inflammatory cytokine, a gene encoding a reporter protein, a gene encoding the inflammatory cytokine, and a gene encoding a proteolytic signal sequence to thereby detect an inflammatory reaction induced upon inflammatory stimulation in the transformant or in the transgenic non-human animal.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: September 8, 2020
    Assignees: TRANSGENIC INC., NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY
    Inventors: Kenichi Yamamura, Takao Iwawaki, Daisuke Oikawa, Tomoo Ishikawa
  • Patent number: 10760107
    Abstract: The purpose of the present invention is to provide an organism having an ergothioneine productivity that is capable of easily producing ergothioneine within a short period of time at a high yield, as compared with a conventional technology, and, therefore, enables ergothioneine production on an industrial scale. This purpose can be achieved by a transformed fungus into which a gene encoding enzyme (1) or genes encoding enzymes (1) and (2) have been inserted and in which the inserted gene(s) are overexpressed. (1) an enzyme catalyzing a reaction of synthesizing hercynyl cysteine sulfoxide from histidine and cysteine in the presence of S-adenosyl methionine, iron (II) and oxygen. (2) An enzyme catalyzing a reaction of synthesizing ergothioneine from hercynyl cysteine sulfoxide using pyridoxal 5?-phosphate as a coenzyme.
    Type: Grant
    Filed: December 25, 2015
    Date of Patent: September 1, 2020
    Assignee: KIKKOMAN CORPORATION
    Inventors: Seiichi Hara, Keiko Kurosawa, Keiichi Ichikawa
  • Patent number: 10753944
    Abstract: The present invention relates to a method for covalently binding a cell surface protein and a ligand, the ligand being capable of specifically binding to the cell surface protein, the method consisting essentially of contacting the living cells expressing the cell surface protein with the ligand comprising at least one furan moiety, thereby covalently binding the cell surface protein and the ligand.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: August 25, 2020
    Assignee: UNIVERSITEIT GENT
    Inventors: Annemieke Madder, Christophe Ampe, Willem Vannecke, Marleen Van Troys
  • Patent number: 10752931
    Abstract: The invention further relates to a process for the enzymatic synthesis of an (oligo)peptide. The invention relates to a method for designing an enzymatic synthesis process of an (oligo)peptide, comprising identifying two or more (oligo)peptide fragments of an (oligo)peptide, which fragments are (oligo)peptides suitable for preparing the (oligo)peptide by enzymatic condensation of the two or more peptide fragments using a ligase. The invention relates to a method for designing an enzymatic synthesis process of a cyclic (oligo)peptide, comprising identifying a non-cyclic (oligo)peptide from which the cyclic (oligo)peptide can be prepared by cyclisation, catalysed by a cyclase. The invention further relates to a process for the enzymatic synthesis of an (oligo)peptide.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: August 25, 2020
    Assignee: ENZYPEP B.V.
    Inventors: Timo Nuijens, Peter Jan Leonard Mario Quaedflieg
  • Patent number: 10745713
    Abstract: Methods and compositions for deploying refuge seeds together with transgenic crop seeds are provided. The refuge seeds can be non-transgenic seeds of a similar variety to that of the transgenic crop seeds, or the refuge seeds can be a transgenic variety, but in either case lacking a transgenic trait conferring pest protection found in the transgenic crop seeds.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 18, 2020
    Assignee: Monsanto Technology LLC
    Inventors: Graham Head, Jay C. Pershing, John K. Soteres
  • Patent number: 10718001
    Abstract: Disclosed is a host cell for producing a recombinant peptide, polypeptide or protein of interest, wherein the host cell includes at least 2 copies of a nucleic acid sequence encoding a poison protein; and to the use thereof for producing peptides, polypeptides or proteins of interest.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: July 21, 2020
    Assignee: DELPHI GENETICS
    Inventors: Cedric Szpirer, Jonathan Cavrenne, Benjamin Michel
  • Patent number: 10717992
    Abstract: The invention provides compositions and methods for regulating thermogenesis and muscle inflammation through modulation of Metrnl and/or Metrn activity and/or expression. Also provided are methods for preventing or treating metabolic disorders and muscle inflammation disorders in a subject through modulation of Metrnl and/or Metrn activity and/or expression. Further provided are methods for identifying compounds that are capable of treating metabolic disorders and muscle inflammation disorders by modulating Metrnl and/or Metrn activity and/or expression.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: July 21, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Rajesh R. Rao, Jonathan Z. Long
  • Patent number: 10711290
    Abstract: The purpose of the present invention is to provide an organism having an ergothioneine productivity that is capable of easily producing ergothioneine within a short period of time at a high yield, as compared with a conventional technology, and, therefore, enables ergothioneine production on an industrial scale. This purpose can be achieved by a transformed fungus into which a gene encoding enzyme (1) or genes encoding enzymes (1) and (2) have been inserted and in which the inserted gene(s) are overexpressed. (1) an enzyme catalyzing a reaction of synthesizing hercynyl cysteine sulfoxide from histidine and cysteine in the presence of S-adenosyl methionine, iron (II) and oxygen. (2) An enzyme catalyzing a reaction of synthesizing ergothioneine from hercynyl cysteine sulfoxide using pyridoxal 5?-phosphate as a coenzyme.
    Type: Grant
    Filed: December 25, 2015
    Date of Patent: July 14, 2020
    Assignee: KIKKOMAN CORPORATION
    Inventors: Seiichi Hara, Keiko Kurosawa, Keiichi Ichikawa
  • Patent number: 10709758
    Abstract: Disclosed are synthetic peptides and peptide compositions, including peptide conjugates, that can ameliorate and/or block the cytotoxicity of Clostridium difficile toxin B(TcdB), and methods of their use for inhibiting the activity of Clostridium difficile toxin B(TcdB) and protecting against damage during Clostridium difficile toxin B(TcdB) disease, and/or for use as cell penetrating peptides for enhancing the delivery of particular heterogenous molecules into cells.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: July 14, 2020
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Jimmy D. Ballard, Jason L. Larabee
  • Patent number: 10702559
    Abstract: Described herein are compositions and methods relating to engineered bacteria which have a modified Type 3 Secretion System (T3SS) which permits them to deliver proteins to the extracellular space (e.g., as opposed to the intracellular space of a target cell as done with a wild-type T3SS). In some embodiments, the engineered bacteria comprise a transgenic T3SS. In some embodiments, the delivered protein is non-native or transgenic with respect to the engineered bacteria.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: July 7, 2020
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Cammie Lesser, Analise Reeves
  • Patent number: 10689666
    Abstract: The present invention discloses a genus of insect inhibitory proteins that exhibit properties directed to controlling Lepidopteran and/or Hemipteran crop pests, methods of using such proteins, nucleotide sequences encoding such proteins, methods of detecting and isolating such proteins, and their use in agricultural systems.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: June 23, 2020
    Assignee: MONSANTO TECHNOLOGY LLC
    Inventors: David J. Bowen, Catherine Chay, Artem Evdokimov, Stanislaw Flasinski, Uma R. Kesanapalli, Megan N. Schroder, Rachael N. Slightom, Nengbing Tao, Andrew M. Wollacott
  • Patent number: 10690671
    Abstract: The present invention provides methods for producing disulfide oxidoreductase A (DsbA) and disulfide oxidoreductase C (DsbC) polypeptides at very high levels of purity. Also provided are ultrapure DsbA and DsbC and methods of using same, e.g., for use in immunoassays to show removal of DsbA and DsbC from biologics produced in bacteria.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: June 23, 2020
    Assignee: Genentech, Inc.
    Inventors: Marc Wong, Liliana T. Yee, Amy Lim, Chris B. Fong
  • Patent number: 10683473
    Abstract: A bacteria referred to here as Bacillus subtilis 6A-1 is provided, compositions thereof and processes for use of the bacteria, spores, cells, extracts and enzymes. The compositions which comprise the bacteria, spores, cells, extracts and/or enzymes are capable of degrading polysaccharides. Such compositions are capable of degrading cellulose, including plant-produced cellulose, microcrystalline cellulose and carboxymethyl cellulose. The bacteria produces at least two cellulose-degrading protein fractions. Cellulose degrading activity continues across pH2 to pH13.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: June 16, 2020
    Assignee: Agri-King, Inc.
    Inventors: Gbenga Ayangbile, Mary Grzemski, James F. Tobey, Jr., David Spangler, Lucas Krueger
  • Patent number: 10683559
    Abstract: Provided herein are GPCR-based chemical biosensors that can have a sensing unit, a processing unit, and a response unit that can be used to detect a chemical of interest. Also provided herein are methods of making and using the GPCR-based chemical biosensors.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: June 16, 2020
    Assignee: Georgia Tech Research Corporation
    Inventors: Pamela Peralta-Yahya, Kuntal Mukherjee, Souryadeep Bhattacharyya, Stephen Sarria
  • Patent number: 10676726
    Abstract: Disclosed herein are CRISPR/Cas9-based gene activation systems that include a fusion protein of a Cas9 protein and a protein having histone acetyltransferase activity, and methods of using said systems.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: June 9, 2020
    Assignee: Duke University
    Inventors: Charles A. Gersbach, Isaac Hilton
  • Patent number: 10676507
    Abstract: Peptides and compositions comprising the peptides, and more particularly, a peptide effective in anti-inflammation, anti-fibrosis, wound healing, and anti-cancer treatment, and a composition including the same are described. The peptides provided herein and the compositions comprising the peptides exhibit an effect of alleviating, preventing, or treating inflammation, fibrosis, wounds, and symptoms of diseases such as cancer including these symptoms, and thus may provide a method of preventing or treating associated diseases.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: June 9, 2020
    Assignee: GEMVAX & KAEL CO., LTD.
    Inventor: Sang Jae Kim
  • Patent number: 10675331
    Abstract: The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: June 9, 2020
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Haesun Kim, Anthony O. Caggiano
  • Patent number: 10670609
    Abstract: A method for tracking calcium flux of a eukaryotic cell. The method includes growing the eukaryotic cell in the presences of a ytterbium salt in solution and spectroscopically measuring ytterbium in the eukaryotic cell.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: June 2, 2020
    Inventors: Jingbo Liu, Sajid Bashir, Jeffrey C. Wigle
  • Patent number: 10669313
    Abstract: Provided herein is a multitarget-directed bio-inorganic hybrid structure. The hybrid structure is based on carbon nanotubes, and includes: carbon nanotubes; and two or more peptides bound to a surface of the carbon nanotubes and each independently interacting with different target molecules.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: June 2, 2020
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Yong Beom Lim, Woo Jin Jeong
  • Patent number: 10668125
    Abstract: Disclosed is a peptide of the following (a) or (b): (a) a peptide containing an amino acid sequence including a sequence set forth in any one of SEQ ID NOS: 1, 2, 3, and 4; and (b) a peptide containing an amino acid sequence including a sequence having at least 60% identity with a sequence set forth in any one of SEQ ID NOS: 1, 2, 3, and 4, the peptide having highly-shifted accumulation to pancreatic cancer cells and tissues.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: June 2, 2020
    Assignee: Niigata University
    Inventors: Eisaku Kondo, Ken Saito
  • Patent number: 10669308
    Abstract: Provided is a method of treating a protein to be renatured, including: (1) mixing the protein to be renatured with a denaturing solution containing a denaturing reagent; (2) incubating a resulting mixture at such a low temperature that the denaturing agent is gradually precipitated from the denaturing solution, resulting in a decreasing concentration gradient of the denaturing agent and an increasing concentration of a renatured protein or its precursor in the denaturing solution with a decreasing volume; and (3) obtaining at least one of the renatured protein and its precursor.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: June 2, 2020
    Inventor: Peng Zhang
  • Patent number: 10662439
    Abstract: Insecticidal proteins exhibiting toxic activity against Coleopteran and Lepidopteran pest species are disclosed, and include, but are not limited to, TIC3668, TIC3669, TIC3670, TIC4076, TIC4078, TIC4260, TIC4346, TIC4826, TIC4861, TIC4862, TIC4863, and TIC-3668-type proteins. DNA molecules and constructs are provided which contain a polynucleotide sequence encoding one or more of the disclosed TIC3668-type proteins. Transgenic plants, plant cells, seed, and plant parts resistant to Lepidopteran and Coleopteran infestation are provided which contain polynucleotide sequences encoding the insecticidal proteins of the present invention. Methods for detecting the presence of the polynucleotides or the proteins of the present invention in a biological sample, and methods of controlling Coleopteran and Lepidopteran species pests using any of the TIC3668-type insecticidal proteins are also provided.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: May 26, 2020
    Assignees: Monsanto Technology LLC, Timothy K. Ball, Esq.
    Inventors: Gregory J. Bean, David J. Bowen, Catherine A. Chay, Arlene R. Howe, Jason S. Milligan, Yong Yin
  • Patent number: 10633682
    Abstract: The present disclosure is directed to microorganisms that are genetically modified to express at least one exogenous enzyme involved in D-glucosamine uptake and metabolism. Methods for the production of an exopolysaccharide are also disclosed. The exopolysaccharide comprises N-acetylglucosamine and D-glucose and may be used as a bioresorbable implant for soft tissue repair, replacement, or augmentation.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: April 28, 2020
    Assignee: DePuy Synthes Products, Inc.
    Inventor: Douglas D. Buechter
  • Patent number: 10619144
    Abstract: The present invention relates to a recombinant fungal host cell comprising at least one first polynucleotide encoding a polypeptide of interest; and one or more second polynucleotide encoding a fungal PepC protease, wherein the one or more second polynucleotide is operably linked to a regulated heterologous promoter, as well as a method for producing a polypeptide of interest, comprising cultivating said fungal host cell.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: April 14, 2020
    Assignee: Novozymes A/S
    Inventors: Hiroshi Teramoto, Hiroaki Udagawa, Jan Lehmbeck, Michael Lynge Nielsen
  • Patent number: 10611806
    Abstract: Nucleotide sequences are disclosed that encode novel chimeric insecticidal proteins exhibiting Lepidopteran inhibitory activity. Particular embodiments provide compositions and transformed plants, plant parts, and seeds containing the recombinant nucleic acid molecules encoding one or more of the chimeric insecticidal proteins.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: April 7, 2020
    Assignee: Monsanto Technology LLC
    Inventors: James A. Baum, Thomas A. Cerruti, Crystal L. Dart, Leigh H. English, Stanislaw Flasinski, Xiaoran Fu, Victor M. Guzov, Arlene R. Howe, Jay P. Morgenstern, James K. Roberts, Sara A. Salvador, Jinling Wang
  • Patent number: 10604771
    Abstract: Disclosed herein are methods and compositions for delivery of engineered nucleases and donor molecules into the genome of a cell.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: March 31, 2020
    Assignees: Sangamo Therapeutics, Inc., University of Southern California
    Inventors: Paula M. Cannon, Colin Michael Exline, Michael C. Holmes
  • Patent number: 10604727
    Abstract: A bacteria referred to here as Bacillus subtilis 6A-1 is provided, compositions thereof and processes for use of the bacteria, spores, cells, extracts and enzymes. The compositions which comprise the bacteria, spores, cells, extracts and/or enzymes are capable of degrading polysaccharides. Such compositions are capable of degrading cellulose, including plant-produced cellulose, microcrystalline cellulose and carboxymethyl cellulose. The bacteria produces at least two cellulose-degrading protein fractions. Cellulose degrading activity continues across pH2 to pH13.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: March 31, 2020
    Assignee: Agri-King, Inc.
    Inventors: Gbenga Ayangbile, Mary Grzemski, James F. Tobey, Jr., David Spangler, Lucas Krueger
  • Patent number: 10597679
    Abstract: Some aspects of this disclosure provide compositions, methods, systems, and kits for controlling the activity and/or improving the specificity of RNA-programmable endonucleases, such as Cas9. For example, provided are guide RNAs (gRNAs) that are engineered to exist in an “on” or “off state, which control the binding and hence cleavage activity of RNA-programmable endo-nucleases. Some aspects of this disclosure provide mRNA-sensing gRNAs that modulate the activity of RNA-programmable endo-nucleases based on the presence or absence of a target mRNA. Some aspects of this disclosure provide gRNAs that modulate the activity of an RNA-programmable endonuclease based on the presence or absence of an extended DNA (xDNA).
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: March 24, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, Johnny Hao Hu
  • Patent number: 10597437
    Abstract: Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular taste stimulus in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: March 24, 2020
    Assignee: Firmenich Incorporated
    Inventors: Jon Elliot Adler, Xiaodong Li, Lena Luukkonen, Shawn O'Connell, Sergey Zozulya
  • Patent number: 10590395
    Abstract: Provided is a mutant protein obtained by mutating a specific amino acid residue of HMGR, a rate-limiting enzyme of isoprene monomer biosynthesis in the polyisoprenoid biosynthesis pathway. The present invention relates to a mutant protein, wherein at least one amino acid residue selected from the group consisting of amino acid residues at positions 91, 225, 257, 287, 339, 411, 470, 509 and 574 of the Arabidopsis thaliana 3-hydroxy-3-methylglutaryl CoA reductase shown by SEQ ID NO:1 and amino acid residues at positions corresponding to the foregoing in 3-hydroxy-3-methylglutaryl CoA reductase is deleted or replaced with another amino acid residue.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: March 17, 2020
    Assignees: OSAKA UNIVERSITY, SUMITOMO RUBBER INDUSTRIES, LTD.
    Inventors: Keiko Suzuki, Jekson Robertlee, Toshiya Muranaka, Keiji Takagi, Yukino Inoue, Kazuhisa Fushihara
  • Patent number: 10583169
    Abstract: The invention relates, in part, to methods and compositions that are useful to modulate metabolic function of cells in vivo or in vitro. In some aspects the invention includes methods and/or compositions that increase metabolism in cells, tissues, organs, and/or subjects. In certain aspects the invention includes methods and/or compositions useful to decrease metabolism in cells, tissues, organs, and/or in subjects.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: March 10, 2020
    Assignee: University of Vermont and State Agricultural College
    Inventors: Mercedes Rincon, Ketki M. Hatle
  • Patent number: 10583181
    Abstract: The invention relates to cell stimulatory fusion proteins and DNA sequences, vectors comprising at least two agonists of TNF/TNFR super family, immunoglobulin super family, cytokine family proteins and optional antigen combination. Instructions for use of these proteins and DNA constructs as immune adjuvants and vaccines for treatment of various chronic diseases such as viral infection are also provided. Additionally, the use of these protein and DNA constructs as immune suppressant for treatment of various chronic diseases, such as autoimmunity and organ transplant rejection, is also illustrated.
    Type: Grant
    Filed: February 11, 2018
    Date of Patent: March 10, 2020
    Inventor: Atsuo Ochi
  • Patent number: 10577619
    Abstract: The present disclosure relates to certain polypeptides derived from prokaryotic DGT enzymes, and nucleic acids useful in encoding the same.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: March 3, 2020
    Assignee: Dow AgroSciences LLC
    Inventors: Justin M. Lira, Robert Cicchillo, Carla N Yerkes, Andrew E Robinson
  • Patent number: 10550389
    Abstract: The present invention is drawn to methods and compositions for treating inflammatory disorders of the lower airways, comprising administering an effective amount of an agent, which modulates the expression and/or activity of a proinflammatory cytokine or fragment thereof, preferably in a human. The proinflammatory cytokine contemplated by the invention includes IL-1, IL-6, IL-8 and TNF-alpha. The present invention describes a kit comprising a delivery device and a pharmaceutical composition for administration of the agent. The pharmaceutical composition includes at least one proinflammatory cytokine inhibitor, optionally one or more additional active ingredients, and at least one pharmaceutically active carrier. The delivery device further comprises a nebulizer, an inhaler, a powder dispenser, an intrapulmonary aerosolizer and a sub-miniature aerosolizer.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: February 4, 2020
    Inventor: Roy C. Levitt
  • Patent number: 10544191
    Abstract: Methods and compositions are provided for generating macrocyclic peptides from genetically encoded, ribosomally produced polypeptide precursors. Also provided are nucleic acid molecules, polypeptides, and methods for generating combinatorial libraries of macrocyclic peptides. These methods can be used to produce vast libraries of conformationally constrained peptide ligands as well as facilitate the functional screening of these libraries to identify compound(s) with desired activity properties.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: January 28, 2020
    Assignee: University of Rochester
    Inventor: Rudi Fasan
  • Patent number: 10533197
    Abstract: Using as a carbon source a long chain fatty acid which has not necessarily been efficaciously used in industry, culture of a microorganism and production of a substance by the microorganism are industrially efficiently carried out. A microorganism is cultured in the presence of a carbon source including anyone of the following compositions: (1) a fatty acid composition containing at least two fatty acids selected from the group consisting of lauric acid, myristic acid, palmitic acid and oleic acid; and (2) a mixed composition containing at least one fatty acid selected from the group consisting of lauric acid, myristic acid, palmitic acid and oleic acid, and a fat and oil, and having a content of the fatty acid of not less than 10% by weight.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: January 14, 2020
    Assignee: KANEKA CORPORATION
    Inventors: Tetsuya Fujiki, Shunsuke Sato
  • Patent number: 10527620
    Abstract: Methods and compositions for detecting BoNT/A enzymatic activity in tissues or a tissue sample are described herein. The invention encompasses antibodies that bind preferentially to BoNT/A cleaved SNAP25 and is able to preferentially detect BoNT/A cleaved SNAP25, as compared to intact (non-cleaved) SNAP25, in a tissue sample.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: January 7, 2020
    Assignee: Allergan, Inc.
    Inventors: Ron S. Broide, Brian Cai, Ester Fernandez-Salas, Joseph Francis, Catherine Rheaume
  • Patent number: 10526609
    Abstract: The present invention provides nucleic acid and protein sequences that enhance the expression of fusion proteins by host cells, and in particular bacterial species, together with methods use thereof. While described hereinafter in terms of expression of fusion proteins by Listeria monocytogenes, the present invention is applicable to expression of fusion proteins generally.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: January 7, 2020
    Assignee: ADURO BIOTECH, INC.
    Inventors: Peter M. Lauer, William G. Hanson
  • Patent number: 10520491
    Abstract: Disclosed herein are cell lines transformed to express G-Protein Coupled Receptor GPCR22 and uses thereof for identifying guanosine analogues and/or other ligands to the receptor. In particular, techniques for transforming Drosophila Schneider 2 cells and human astrocytoma 1321N1 cell to express GPCR22 are disclosed as well as transformed cells lines. The transformed cell lines of the instant disclosure may be useful in identifying guanosine analogues and functional equivalents thereof.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: December 31, 2019
    Assignee: LIBRAMEN NATURALS INC.
    Inventors: Michel P. Rathbone, Shucui Jiang, Francesco Caciagli, Renata Ciccarelli, Patrizia Ballerini, Patrizia Di Iorio, Patricia Giuliani, Iolanda D'Alimonte
  • Patent number: 10507236
    Abstract: The present invention is directed generally to chimeric proteins that can facilitate targeting of nanoparticulate carriers to antigen presenting cells, and to nanoparticulate carriers comprising these chimeric proteins. The invention is also directed to methods of internalizing an antigen in an antigen presenting cell, and methods of eliciting an immune response to an antigen in a subject, using the nanoparticulate carriers comprising the chimeric proteins.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: December 17, 2019
    Assignees: Lipotek Pty Ltd, The Australian National University
    Inventors: Jason David Price, Christopher Parish, Ines Atmosukarto
  • Patent number: 10500288
    Abstract: Disclosed are isolated cytotoxic peptides having similar sequences as the basic region (BR) of Hexamethylene Bisacetamide Inducible Protein 1 (HEXIM1). Preferred embodiments include QLGKKKHRRRPSKKKRHW (SEQ ID No: 3). QLGRRRHRRRPSRRRRHW (SEQ ID No: 4) and QLGKKILAARPSKKKRHW (SEQ ID No: 5). Also encompassed are isolated nucleic acid molecules encoding for the claimed peptides, vectors comprising the isolated nucleic acids, compositions comprising peptides conjugated to cell-targeting or penetrating peptides or antibodies, nucleic acid molecules or vectors expressing conjugates thereof; methods of treating or preventing diseases or conditions, including cancers and obesity as well as a method of eliminating undifferentiated stem cells.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: December 10, 2019
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Sheng-Hao Chao
  • Patent number: 10494676
    Abstract: The present invention relates to an in vitro process for the diagnosis of prostate cancer and other tumor types in exosomes obtained from a body fluid which comprises a) concentrating the exosomes and other extracellular vesicles from a body fluid of a patient, b) extraction of total RNA from the exosomes obtained in step a), c) conversion of the RNA obtained in step b) to cDNA, d) amplification of the cDNA obtained in step c) with a polymerase chain reaction whereby primers derived from the AGR2 nucleotide sequence or the complement thereof are used, and e) determining whether in the amplification product variants of the AGR2 gene can be identified.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: December 3, 2019
    Assignees: Albert-Ludwigs-Universitaet Freiburg, Karlsruher Institut Für Technologie
    Inventors: Irina Nazarenko, Andrew Cato, Antje Neeb, Stefanie Bormann, Martin Schoenthaler, Arkadiusz Miernik, Malte Kroenig, Konrad Wilhelm, Benjamin Haenselmann, Simon Hefele
  • Patent number: 10487366
    Abstract: The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease, prognostic evaluation and therapy of acute myeloid leukaemia (AML).
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: November 26, 2019
    Inventors: Brunangelo Falini, Cristina Mecucci
  • Patent number: 10487112
    Abstract: A Pediococcus acidilactici derived antimicrobial hexapeptide and a preparation method thereof are disclosed herein. The antimicrobial peptide ENGEEE (SEQ ID NO: 1) is reported for the first time. Antimicrobial peptide lactein R16 has good pH stability and thermal stability, has an effect on inhibiting Escherichia coli, Listeria monocytogenes and Staphylococcus aureus and is capable of effectively reducing the amount of the Escherichia coli in soybean meal. Secondly, the antimicrobial peptide lactein R16 has a certain effect on proliferating Saccharomyces cerevisiae and Lactobacillus plantarum and has certain capability of clearing hydrogen peroxide, hydroxyl radicals, DPPH radicals and superoxide anions. The antimicrobial peptide lactein R16 can be used for biological control and can be used as a feed additive to play important roles in substituting antibiotics and solving the feed safety problem.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: November 26, 2019
    Assignee: Jiangnan University
    Inventors: Jian Lu, Guolin Cai, Juan Wang, Dewei Zhu
  • Patent number: 10485860
    Abstract: The present invention provides proteins/genes, which are essential for survival, and consequently, for virulence of Streptococcus pneumoniae in vivo, and thus are ideal vaccine candidates for a vaccine preparation against pneumococcal infection. Further, also antibodies against said protein(s) are included in the invention.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: November 26, 2019
    Assignee: Stichting Katholieke Universiteit / Radboud University Nijmegen Medical Centre
    Inventors: Hester Jeanette Bootsma, Pieter Jan Burghout, Peter Wilhelmus Maria Hermans, Johanna Jacoba Elisabeth Bijlsma, Oscar Paul Kuipers, Tomas Gerrit Kloosterman
  • Patent number: 10465255
    Abstract: Nucleic acid oligonucleotide sequences are disclosed which include amplification oligomers and probe oligomers which are useful for detecting multiple types of human papillomaviruses (HPV) associated with cervical cancer. Methods for detecting multiple HPV types in biological specimens by amplifying HPV nucleic acid sequences in vitro and detecting the amplified products are disclosed.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: November 5, 2019
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Sylvia A. Norman, Jennifer J. Bungo, William L. Hanna, Neeraj P. Rao
  • Patent number: 10465208
    Abstract: The present invention provides for a mechanism to completely replace the electron accepting function of glycerol formation with an alternative pathway to ethanol formation, thereby reducing glycerol production and increasing ethanol production. In some embodiments, the invention provides for a recombinant microorganism comprising a down-regulation in one or more native enzymes in the glycerol-production pathway. In some embodiments, the invention provides for a recombinant microorganism comprising an up-regulation in one or more enzymes in the ethanol-production pathway.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: November 5, 2019
    Assignee: Lallemand Hungary Liquidity Management LLC
    Inventors: Arthur J. Shaw, IV, Aaron Argyros, Trisha Barrett